Literature DB >> 32293745

Predictive accuracy of markers or risk scores for interval censored survival data.

Yuan Wu1, Xiaofei Wang1, Jiaxing Lin1, Beilin Jia2, Kouros Owzar1.   

Abstract

Methods for the evaluation of the predictive accuracy of biomarkers with respect to survival outcomes subject to right censoring have been discussed extensively in the literature. In cancer and other diseases, survival outcomes are commonly subject to interval censoring by design or due to the follow up schema. In this article, we present an estimator for the area under the time-dependent receiver operating characteristic (ROC) curve for interval censored data based on a nonparametric sieve maximum likelihood approach. We establish the asymptotic properties of the proposed estimator and illustrate its finite-sample properties using a simulation study. The application of our method is illustrated using data from a cancer clinical study. An open-source R package to implement the proposed method is available on Comprehensive R Archive Network.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Sieve estimation; area under ROC curve; interval censoring; joint distribution

Mesh:

Substances:

Year:  2020        PMID: 32293745      PMCID: PMC7806230          DOI: 10.1002/sim.8547

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Time-dependent ROC curves for censored survival data and a diagnostic marker.

Authors:  P J Heagerty; T Lumley; M S Pepe
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Non-parametric estimation of a time-dependent predictive accuracy curve.

Authors:  P Saha-Chaudhuri; P J Heagerty
Journal:  Biostatistics       Date:  2012-06-25       Impact factor: 5.899

3.  Survival model predictive accuracy and ROC curves.

Authors:  Patrick J Heagerty; Yingye Zheng
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  Time-dependent ROC analysis under diverse censoring patterns.

Authors:  Jialiang Li; Shuangge Ma
Journal:  Stat Med       Date:  2011-01-17       Impact factor: 2.373

5.  Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Authors:  Martin J Edelman; Xiaofei Wang; Lydia Hodgson; Richard T Cheney; Maria Q Baggstrom; Sachdev P Thomas; Ajeet Gajra; Erin Bertino; Karen L Reckamp; Julian Molina; Joan H Schiller; Kisha Mitchell-Richards; Paula N Friedman; Jon Ritter; Ginger Milne; Olwen M Hahn; Thomas E Stinchcombe; Everett E Vokes
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

Review 6.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

7.  Receiver operating characteristic curve estimation for time to event with semicompeting risks and interval censoring.

Authors:  Hélène Jacqmin-Gadda; Paul Blanche; Emilie Chary; Célia Touraine; Jean-François Dartigues
Journal:  Stat Methods Med Res       Date:  2014-05-06       Impact factor: 3.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.